← back to search

Donald L. Durden

Atrium Medical Cente · US
Area of research
Molecular Biology · Pulmonary and Respiratory Medicine
Research interest
Research interests include PI3K/AKT/mTOR signaling in cancer, Protein Degradation and Inhibitors, Advanced Breast Cancer Therapies, and Protein Kinase Regulation and GTPase Signaling.
h-index
43
citations
6,555
works
179
NIH funding
primary concept
email

Recent publications

Binding of the SARS-CoV-2 envelope E protein to human BRD4 is essential for infection
Structure 2022cited by 33position: middledoi
COVID-19 and Cancer Comorbidity: Therapeutic Opportunities and Challenges
Theranostics 2020cited by 129position: middledoi
Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System
Journal of Oncology 2019cited by 112position: lastdoi
Induction of autophagy by PI3K/MTOR and PI3K/MTOR/BRD4 inhibitors suppresses HIV-1 replication
Journal of Biological Chemistry 2018cited by 63position: middledoi
Dual-activity PI3K–BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis
Proceedings of the National Academy of Sciences 2017cited by 119position: middledoi
The differential ability of asparagine and glutamine in promoting the closed/active enzyme conformation rationalizes the Wolinella succinogenes L-asparaginase substrate specificity
Scientific Reports 2017cited by 35position: middledoi
Vascular remodeling underlies rebleeding in hemophilic arthropathy
American Journal of Hematology 2015cited by 98position: middledoi
A Macrophage-Dominant PI3K Isoform Controls Hypoxia-Induced HIF1α and HIF2α Stability and Tumor Growth, Angiogenesis, and Metastasis
Molecular Cancer Research 2014cited by 128position: lastdoi
Rac2 Controls Tumor Growth, Metastasis and M1-M2 Macrophage Differentiation In Vivo
PLoS ONE 2014cited by 125position: lastdoi
Synthesis and Cancer Stem Cell-Based Activity of Substituted 5-Morpholino-7<i>H</i>-thieno[3,2-<i>b</i>]pyran-7-ones Designed as Next Generation PI3K Inhibitors
Journal of Medicinal Chemistry 2013cited by 54position: lastdoi
Pediatric Phase II Trials of Poly-ICLC in the Management of Newly Diagnosed and Recurrent Brain Tumors
Journal of Pediatric Hematology/Oncology 2013cited by 48position: lastdoi
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
European Journal of Cancer 2012cited by 134position: middledoi
Distinct roles for fibroblast growth factor signaling in cerebellar development and medulloblastoma
Oncogene 2012cited by 35position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Shweta Joshi · University of California San Diego7 papers (2013–2019) · 3 papers (2012–2017)Alok R. Singh · Sorrento Therapeutics (United States)3 papers (2014–2017)Muamera Zulcic · University of California, San Diego2 papers (2014–2014)Tatiana G. Kutateladze · University of Colorado Hospital2 papers (2017–2022)Siddappa N. Byrareddy · Nebraska Medical Center2 papers (2020–2022)Guillermo A. Morales · University of Arizona2 papers (2013–2017)Laurent O. Mosnier · Scripps Research Institute1 papers (2015–2015)Jacques Côté · Université Laval1 papers (2022–2022)Mohamad Zandian · University of Colorado Denver1 papers (2022–2022)Daruka Mahadevan · University of Arizona1 papers (2012–2012)Wayne B. Harris · Center for the Study of Democracy1 papers (2012–2012)Shirley L. Markant · National Cancer Institute1 papers (2012–2012)Eugene Hwang · Center for Cancer and Blood Disorders1 papers (2012–2012)Arnon Lavie · University of Illinois Chicago1 papers (2017–2017)John R. Crawford · Children's Hospital of Orange County1 papers (2013–2013)Diane Rensvold · University of Arizona1 papers (2012–2012)Hien Anh Thi Nguyen · University of Illinois Chicago1 papers (2017–2017) · 1 papers (2022–2022) · 1 papers (2012–2012)